Pfizer Inc. (PFE)
NYSE: PFE · Real-Time Price · USD
25.09
+0.06 (0.24%)
At close: Dec 26, 2025, 4:00 PM EST
25.07
-0.02 (-0.08%)
After-hours: Dec 26, 2025, 6:51 PM EST
Pfizer Revenue
Pfizer had revenue of $16.65B in the quarter ending September 28, 2025, a decrease of -5.92%. This brings the company's revenue in the last twelve months to $62.79B, up 3.89% year-over-year. In the year 2024, Pfizer had annual revenue of $63.63B with 6.84% growth.
Revenue (ttm)
$62.79B
Revenue Growth
+3.89%
P/S Ratio
2.26
Revenue / Employee
$775,123
Employees
81,000
Market Cap
142.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 63.63B | 4.07B | 6.84% |
| Dec 31, 2023 | 59.55B | -41.62B | -41.14% |
| Dec 31, 2022 | 101.18B | 19.89B | 24.46% |
| Dec 31, 2021 | 81.29B | 39.64B | 95.16% |
| Dec 31, 2020 | 41.65B | 746.00M | 1.82% |
| Dec 31, 2019 | 40.91B | 80.00M | 0.20% |
| Dec 31, 2018 | 40.83B | -11.72B | -22.31% |
| Dec 31, 2017 | 52.55B | -278.00M | -0.53% |
| Dec 31, 2016 | 52.82B | 3.97B | 8.13% |
| Dec 31, 2015 | 48.85B | -754.00M | -1.52% |
| Dec 31, 2014 | 49.61B | -1.98B | -3.84% |
| Dec 31, 2013 | 51.58B | -3.07B | -5.62% |
| Dec 31, 2012 | 54.66B | -6.38B | -10.45% |
| Dec 31, 2011 | 61.04B | -4.13B | -6.34% |
| Dec 31, 2010 | 65.17B | 15.90B | 32.26% |
| Dec 31, 2009 | 49.27B | 973.00M | 2.01% |
| Dec 31, 2008 | 48.30B | -122.00M | -0.25% |
| Dec 31, 2007 | 48.42B | 47.00M | 0.10% |
| Dec 31, 2006 | 48.37B | 966.00M | 2.04% |
| Dec 31, 2005 | 47.41B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PFE News
- 3 days ago - Pfizer says patient dies after receiving hemophilia drug in trial - Reuters
- 7 days ago - Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound - Seeking Alpha
- 7 days ago - Trump to announce new drug-pricing deals later today - Market Watch
- 8 days ago - Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts - Business Wire
- 8 days ago - Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun - Benzinga
- 9 days ago - AbbVie, several other pharma companies near MFN deal with Trump, sources say - Reuters
- 9 days ago - Pfizer Stock Can Sink More. Here Is How - Forbes
- 9 days ago - Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back - Benzinga